On August 20, AKESO rose 6.49% in regular trading, trading at HK$95.1/share, with turnover of HK$239 million.

On the news front, the company is scheduled to release its interim results on August 27, with market attention focused on the volume ramp-up trajectory and profit elasticity following the approval of ivonescimab's third indication for first-line treatment of advanced squamous non-small cell lung cancer on August 12. Institutions broadly maintain buy ratings, with Nomura setting a target price of HK$138.29 and the average target price across covering analysts at HK$170.79, implying significant upside from the current level.

Following the third indication approval on August 12, the stock experienced consecutive days of profit-taking, retreating over 10% from its recent high. The short-term oversold condition, combined with upcoming earnings expectations, triggered capital re-entry. The rebound also comes amid broader strength in the biotechnology sector, with multiple innovative pharma names posting gains.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)